Breast cancer is the most prevalent malignancy affecting women and ranks second in cancer deaths, where death occurs primarily from metastatic disease. Triple-negative breast cancer (TNBC) is a more aggressive and metastatic subtype of breast cancer that is initially responsive to treatment of microtubule-targeting agents (MTAs) such as taxanes. Recently, we reported the characterization of AMG 900, an orally bioavailable, potent and highly selective pan-aurora kinase inhibitor that is active in multidrug resistant cell lines. In this report, we investigate the activity of AMG 900 alone and in combination with two distinct classes of MTAs ) PTX-r xenografts, in which >50% of the tumors failed to regrow 75 days after the cessation of drug treatment.
Introduction
The step-wise process of somatic cell division ensures faithful segregation of duplicated chromosomes into two equal daughter cells. Deregulation of the cell cycle is a hallmark of cancer, characterized by uncontrolled proliferation and defects in chromosome segregation. The human kinome contains a number of enzymes that specifically regulate mitotic progression and spindle assembly checkpoint (SAC) function, including two members of the aurora family of serine-threonine kinases (aurora-A and -B). Both play unique and essential roles in the G 2 -M phase of the cell cycle and are aberrantly expressed in many human cancers, including breast cancer (1) (2) (3) .
Breast cancer is a heterogeneous disease that can be classified into subtypes with different prognosis and treatment strategies. Global gene expression profiling has defined five distinct subtypes that include luminal A, luminal B, ERBB2-enriched, basal-like, and claudin-low (4, 5) . The latter two non-luminal subtypes that lack expression of estrogen and progesterone hormone receptors (ER and PR) and ERBB2 are referred to as triplenegative breast cancer. The TNBC subtype is characterized by its more aggressive and metastatic nature, high degree of genomic instability, elevated proliferation, and frequent inactivation of p53 (6, 7) . Metastatic breast cancer commonly spreads to the bones, lungs, liver, and the central nervous system and remains incurable in most patients. Transcriptome-based analysis of primary breast cancers has shown that increased expression of AURKA and AURKB correlates with elevated proliferation, ER negativity, and primarily (but not exclusively) poorly differentiated non-luminal tumors (8, 9) . Recently, a protein expression based biomarker algorithm analysis of cell-cycle status showed that aggressive breast cancer subtypes (ERBB2-enriched and triple-negative) were associated with significantly elevated levels of aurora-A, p-histone H3 Ser 10 , Mcm2, Ki67, Geminin, and Plk1 (10) . Amplification of the AURKA gene locus has been observed in a subset of human cancers that includes breast tumors (2) . In HeLa cells, ectopic expression of aurora-A at levels similar to cancer-associated gene amplification induces resistance to paclitaxel (11) . Taken together, the critical role that aurora kinases play in mitosis and their overexpression in MBC make them attractive therapeutic drug targets.
Microtubule-targeting agents such as taxanes are among the most active drugs for the treatment of MBC.
However, treatment frequently fails due to de novo or acquired resistance to taxanes. The underlying causes of cancer resistance are multifactorial and complicated by tumor heterogeneity (12, 13) . One of the intrinsic properties of TNBC cells is their enhanced genomic instability, which can accelerate the generation of resistant subpopulations. One well-characterized mechanism of resistance is the overexpression of the MDR1 gene, which encodes P-glycoprotein (P-gp), a drug-efflux pump capable of efficiently extruding taxanes from cells.
Another mechanism that can render tumor cells resistant to taxanes is β-tubulin modifications caused by mutation or changes in isotype expression (12) (13) (14) . Epothilones, similar to taxanes, activate the SAC and inhibit cell proliferation by stabilizing microtubules. Ixabepilone, an epothilone B analog, has lower susceptibility to P-gp mediated drug efflux and has demonstrated durable clinical activity in MBC tumors resistant to taxanes (15, 16) . Combining two antimitotic agents with distinct modes of action, SAC activation (microtubule stabilizer) versus SAC silencing (aurora-A/B inhibition), may provide an approach to block avenues of resistance and limit a cancer cell's ability to evade death (3, 17) .
Recently, we reported the characterization of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in tumor cell lines that are resistant to taxanes and 3 other aurora kinase inhibitors. AMG 900 was broadly active in multiple tumor xenografts, including 3 multidrug-resistant models (18) . In this report, we explore the activity of AMG 900 alone and in combination with two different classes of MTAs in multidrug resistant TNBC cell lines and xenografts. In vitro, AMG 900 induced polyploidy and apoptosis, and inhibited the growth of P-gp expressing TNBC cells at low nanomolar concentrations. In combination, AMG 900 enhanced the antiproliferative effects of MTAs in TNBC cells in vitro and in established tumor xenografts.
Notably, AMG 900 plus ixabepilone resulted in durable tumor regressions in MDA-MB-231 (F 11 ) PTX-r xenografts compared with either monotherapy. Our data provide preclinical evidence that AMG 900, alone and in combination with MTAs, has the potential to treat patients with metastatic breast cancer.
Materials and Methods
Small molecule inhibitors. AMG 900 N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine) was synthesized at Amgen ( Fig. 1 ) (WO2007087276). Paclitaxel (Sigma), docetaxel (Sanofi-Aventis), and ixabepilone (Bristol-Myers Squibb) were procured from commercial sources and molecular structures have previously been reported (19) .
Cell lines. Human cancer cell lines were obtained from the American Type Culture Collection (ATCC) unless otherwise specified. Cells were authenticated and certified by ATCC. ATCC ensures each cell line is negative for Mycoplasma, bacteria, and fungi contamination; confirms species identity; and conducts DNA profiling and cytogenetic analysis to authenticate each cell line. Cell lines were cultured in media supplemented with 10% specifications. Food, water, and nutritional supplements were offered ad libitum. All drugs were administered based on the individual body weight of each mouse. AMG 900 was formulated as a suspension in 2% HPMC, 1% Tween-80, at pH 2.2. Taxanes were formulated as previously described (21) . Ixabepilone (2 mg/mL stock in supplied diluent) was diluted with Lactated Ringer's solution to 0.5mg/mL prior to dosing.
Tumor xenograft pharmacodynamic assay (p-histone H3). Mice with established MDA-MB-231 (F   11   ) human xenograft tumors were administered a single oral dose of vehicle or AMG 900 at 3.75, 7.5 or 15 mg/kg (n = 3 animals per group). At 3 hours after treatment, tumor tissue was collected and processed as described in Supplementary Material and Methods. Deparaffinized sections were heated in citrate buffer to retrieve antigenicity and stained with an anti-phospho-histone H3 on Ser 10 antibody (Millipore) followed by detection with an anti-rabbit IgG-alexa-568 antibody (Invitrogen) and DAPI. Imaging analysis was performed using a TE2000-PFS inverted microscope imaging system (Nikon) equipped with MetaMorph software. The number of p-histone H3 positive cells (2 image fields per tumor) was determined using a threshold based count algorithm.
Blood was collected from individual mice to determine the concentration of AMG 900 in plasma.
Tumor xenograft efficacy studies. per week using a digital caliper and analytical scale, respectively. Tumor volumes were calculated as previously described (21) . Tumor data were represented by mean tumor volume ± SEM. Tumors were collected and processed for routine histology (see Supplementary Materials and Methods).
Statistical analysis.
For the pharmacodynamic assays, the effects of AMG 900 on p-histone H3 were compared using Factorial ANOVA followed by Dunnett's post hoc test for multiple comparisons as appropriate.
For the single agent efficacy studies, the effects of AMG 900 or docetaxel on tumor growth was assessed by repeated measures analysis of variance (RMANOVA) followed by Dunnett's test for multiple comparisons. For the combination efficacy studies, the effects of AMG 900 in combination with docetaxel or ixabepilone on tumor growth were assessed by separate RMANOVA between the combination group and each of the relevant single agents. In all statistical analysis, differences were considered significant at a P value of <0.05.
Microarray analysis. Total RNA was isolated using the Qiagen RNeasy Mini Kit (Qiagen) and processed detectable by an increase in SubG 1 DNA content. Next, we evaluated the nuclear morphology and centrosome features of cells treated with AMG 900 for 48 hours. Microscopy of MDA-MB-231 cells treated with AMG 900 exhibited enlarged irregular-shaped nuclei with numerous centrosomes detected by antipericentrin antibody ( Supplementary Fig.1 ). The mode of action of AMG 900 on TNBC cells is consistent with inhibition of aurora-B; in that AMG 900 silences the SAC, thus leading to polyploidy and cell death (3).
Cell cycle effects and activity of AMG 900, paclitaxel, and ixabepilone in P-gp-expressing breast cancer cell lines.
We previously reported that AMG 900 was active in P-gp expressing cancer cell lines resistant to taxanes and 3 well-characterized aurora kinase inhibitors (18) . To further investigate these findings, we utilized the highly Fig. 2 ). The ABCB4 gene is located on chromosome 7q21.1, proximal to the ABCB1 gene locus, suggesting that the increase in mRNA expression of both genes may be the result of an amplification on 7q21.1 (22, 23) . (Fig. 3A) . Interestingly, the βIII-tubulin overexpressing DU4475 cells also showed elevated expression of P-gp protein, which may represent a dual mechanism of resistance to taxanes (25, 26) . In preparation for future combination studies, we evaluated the cell cycle effects of AMG 900, paclitaxel, and ixabepilone in the same set of breast cancer cell lines to determine single agent potency. As shown in Figure 3B , AMG 900 induced polyploidy in all four cell lines with ≥4N DNA EC 50 values of 1-2 nmol/L and an associated steep slope factor (>4). The cell cycle effects observed with paclitaxel and ixabepilone showed distinct phenotypes at low and high concentrations.
At lower concentrations of drug, the primary effect was cell death, as measured by an increase in the SubG 1 DNA content. At higher concentrations of drug, the fraction of cells with 4N DNA content increased, indicating a classic mitotic arrest phenotype ( Supplementary Fig. 3A and 3B ). Although the cell cycle profiles were largely similar for each cell line treated with ixabepilone or paclitaxel, the P-gp expressing DU4475 and MDA-MB-231 (F 11 ) PTX-r cells were more sensitive to ixabepilone. Consistent with previous reports, the cell death response observed at lower concentrations of MTAs was likely driven by a transient mitotic arrest and not a sustained mitotic arrest (27) . ) PTX-r cells treated sequentially with either paclitaxel or ixabepilone followed by AMG 900 displayed enhanced inhibition of cell growth, as measured by the decrease in cell number and colony formation ( Fig. 4B and 4C ). The enhanced cell growth inhibition with this combination approach was observed over a narrow concentration range compared with either agent alone, which was anticipated given the cytotoxic nature of both classes of antimitotic agents. In a previous study, we determined the sequential treatment of paclitaxel followed by AMG 900 resulted in only an additive interaction using parental MDA-MB-231 cells (data (Fig. 7C arrows) and few bi-or multi-nucleated cells. In contrast, there appeared to be an increase in the number of multinucleated cells in tumors treated with ixabepilone plus AMG 900 (Fig. 7C arrowheads) . After treatment ceased, the remaining mice (7 of 12) in the combination-treated group were monitored for tumor regrowth.
Four out of seven tumors failed to show rapid tumor regrowth after 75 days off treatment in this group (Fig.   7D ). Together, these data provide evidence that AMG 900 inhibits the activity of aurora-B and suppresses the growth of MDA-MB-231 ( data indicate that AMG 900 has the potential to treat patients with metastatic breast cancer that have become resistant to standard-of-care antimitotic drugs.
Discussion
In this report, we describe the activity of AMG 900, a selective pan-aurora kinase inhibitor that shows promising activity alone and in combination with MTAs against TNBC cell lines and xenograft models. Notably, we provide evidence that AMG 900 possesses superior activity to taxanes in TNBC tumors with multiple modes of resistance. Furthermore, the combination of ixabepilone with AMG 900 leads to durable tumor regressions and limits regrowth of multidrug resistant TNBC xenografts.
In contrast to taxanes, AMG 900 was active in TNBC cell lines expressing high levels of P-gp and βIII-tubulin, suggesting AMG 900 has low susceptibility to P-gp mediated drug efflux and functions independently of altered β-tubulin isotype expression. Our data show that SAC silencing mediated through inhibition of aurora-B activity by AMG 900 at low nanomolar concentrations, leads to polyploidy and apoptosis in multidrug resistant MDA-MB-231 (F 11 ) PTX-r and DU4475 cell lines. Other factors may also contribute to the antiproliferative effects of AMG 900, including cellular senescence and cell death by mitotic catastrophe, giant-cell necrosis, and multipolar cell division (unpublished observations by Marc Payton, 28-31). In breast cancers, p53 is mutated in approximately 25% of cases, with a higher frequency in TNBC (32) . The level of polyploidy induced by AMG 900 treatment was higher in mutant p53 MDA-MB-231 cells compared to wild-type p53 DU4475 cells; this was likely due to activation of the post-mitotic p53-dependent G 1 -checkpoint. Impeding endoreduplication by activating this checkpoint may favor senescence, whereas bypassing this checkpoint (via p53 mutation/deletion) may initiate a more durable p53-independent cell death response (33) . Loss of cell-cycle checkpoint control and elevated proliferation associated with TNBC may represent a vulnerability to drugs that induce mitotic stress, including MTAs and aurora kinases (34) . MTAs and AMG 900 both act directly on cells during mitosis, but they inhibit mitotic progression and induce stress through distinct modes of action. MTAs disrupt microtubule dynamics, resulting in SAC activation, whereas AMG 900 inhibits the activity of both aurora-A and -B, leading to SAC silencing. We hypothesized that by first treating with a MTA, the fraction of cells in mitosis would increase due to SAC activation, rendering the cells more vulnerable to the activity of 11 )-PTX-r cells, suggesting the combined effect of SAC activation follow by SAC silencing may increase mitotic stress and cell lethality. We did not examine AMG 900 in combination with vinca alkaloid class of MTAs because P-gp expressing cancer cells were insensitive to vinblastine; suggesting a low potential for enhancing the activity of AMG 900 (data not shown, 35).
We extended our findings in vivo, demonstrating that MTAs combined with AMG 900 enhanced antitumor activity in both taxane-sensitive and -resistant TNBC xenografts. Notably, we found that sequential treatment with ixabepilone followed by AMG 900 induced durable tumor regressions in the MDA-MB-231 (F 11 ) PTX-r xenografts. Ixabepilone plus AMG 900 induced multinucleation, suggesting the tumor xenograft cells survived after the MTA induced mitotic arrest, becoming multinucleated rather than dying directly from SAC activation alone. There may be other antitumor mechanisms by which ixabepilone and AMG 900 act cooperatively. A recent study showed that ixabepilone was more effective than paclitaxel at blocking tumor angiogenesis in vivo, possibly through inhibiting the proliferation of tumor xenograft-associated mouse endothelial cells overexpressing P-gp (36) . These findings may explain why we observed a more durable in vivo antitumor effect with the ixabepilone and AMG 900 combination. We should note that we did not confirm the antitumor activity of MTAs combined with AMG 900 induced apoptosis, largely because the dynamic and transient nature of apoptosis in vivo made it difficult to select an appropriate time interval to measure programmed cell death in tumor xenograft tissues. It is important to recognize the potential challenge of combining AMG 900 with other MTAs in the clinic due to the likelihood of overlapping toxicities in proliferating tissues (e.g. bone marrow and gastrointestinal mucosa). The negative impact on normal tissue homeostasis could limit the utility of this combination, although prophylactic administration of granulocyte colony-stimulating factor (G-CSF) may help decrease the duration of neutropenia (18) . One area for further investigation will be to evaluate the activity of AMG 900 alone and in combination with MTAs in either patient-derived cancer xenografts or a genetically engineered mouse model of human MBC (37, 38) . These alternative preclinical models may more closely mirror human disease (e.g. tumor heterogeneity, multifactorial nature of MDR) and allow for a more fateful assessment of drug efficacy. drug treatment, cells were washed and cultured in complete media until day 7. B and C, cells were collected and enumerated using an automated cell counter (in duplicate). Mean total cell count is represented as a 3 dimensional column graph, column color denoted by DMSO alone (grey), AMG 900 alone (blue), or MTA alone (dark purple), and combinations (green, red, light blue). In separate wells, cells were stained with crystal violet dye and imaged. 
